Vuk Koprivica, Ph.D.

It was a pleasure to share Clene Nanomedicine, Inc.’s story with Soumya Shashikumar and Vera Kovacevic at Xtalks! Here’s to a future with safe and effective treatments for all neurodegenerative diseases. #endALS #defeatMS #multiplesclerosis #ParkinsonsDisease #RarePediatricDiseases #mitochondrial diseases

47

1 Comment

June 6, 2024 - OniX: Standardizing Global Preclinical Research for Accelerated Innovation In a world where the US, UK, and EU federal governments collectively spend over $600 billion annually on R&D, the sheer volume of data generated daily is staggering. OniX stands at the forefront of harnessing this wealth of knowledge, serving as the premier research knowledge hub that standardizes preclinical data from universities, startups, biotech companies, accelerators, and incubators. By aggregating both public and proprietary data, OniX empowers strategic R&D and business development activities, accelerating the path from innovation to market. https://lnkd.in/d_bPbcD

2

check out today's top news Investorideas.com- News that inspires big investing ideas Transformative #Biopharma #Stocks - Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), Vertex Pharmaceuticals (Nasdaq: VRTX), CRISPR Therapeutics (Nasdaq: CRSP), Recursion (NASDAQ: RXRX) #biotech #pharma #stockstowatch #ai #crispr   July 11, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. (Nasdaq:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. The global biopharmaceutical market size was USD 411.4 Billion in 2022, 436.7 Billion in 2023 and analysts say it will grow at 15, 4% from 2024 to 2033. Looking at key trends in the sector, including AI and CRISPR, Labiotech reports, "2024 stands as a pivotal year that could potentially mark a turning point in the biotech industry. With the right blend of innovation, collaboration, and regulatory oversight, the industry is well-positioned to harness these emerging trends and transform the landscape of healthcare and therapeutic interventions. The future of biotech is not just about technological advancements, but also about how these technologies are integrated responsibly and ethically into our healthcare systems to create a healthier, more sustainable world." Citius Pharmaceuticals, Inc. (Nasdaq:CTXR) just announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date. Leonard Mazur, Chairman and CEO of Citius stated, "Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months. Mino-Lok's strong Phase 3 topline results support its potential to become part of the standard of care for treating catheter-related bloodstream infections. Mino-Lok would also have a first and only advantage in a market with no approved or investigational products for salvaging infected central venous catheters. For LYMPHIR™, the FDA is currently reviewing our Biologics License Application, with an expected decision on August 13th. We are preparing for near-term commercialization of LYMPHIR if approved. These near-term catalysts should enable the company to optimize its current cash runway, future cash needs, as well as create potential non-dilutive cash opportunities." Paid news dissemination for Citius Pharmaceuticals.

4

Watch out how AI/ML and autonomous continuous flow chemistry will augment this!

1

What a fascinating and productive workshop we are having at Cold Spring Harbor Laboratory in New York from June 3 to 6th, titled "Using Cell-free Systems to Synthesize and Express Bacteriophage Genomes: Practical Biomanufacturing for Bioscience Educators." This event, held at the DNA Learning Center NYC at City Tech, Brooklyn, is empowering bioscience educators with the tools and knowledge to introduce students to innovative biomanufacturing techniques. Under the guidance of Vincent Noireaux, participants are exploring a cell-free transcription-translation (TXTL) system to manufacture bacteriophages with new host specificities. This workshop not only honors the legacy of pioneering bacteriophage research at Cold Spring Harbor but also highlights the contemporary applications of phages in tackling multi-drug resistant bacterial infections, improving food safety, and advancing biotechnological innovations. Through hands-on experiments, attendees are engineering T7 phages to infect new E. coli hosts, conducting PCR mutagenesis, and utilizing nanopore DNA sequencing to investigate phage infectivity, making this a truly transformative experience for all involved. Bacteriophages, once again at the forefront of biotechnology, offer solutions to critical challenges in pharmaceuticals, agriculture, and food safety. By equipping educators with cutting-edge techniques to manufacture phages with new host specificities.

30

2 Comments

Have you been wondering about use cases for #GenerativeAI for Clinical and Regulatory Medical Writing in #Pharma or #Biotech? Check out this publication! #GenAI4Pharma #IAmAnAdvisor

8

More on the question of why Z-DNA is important in human biology. The paper with a colleague David Pisetsky from Duke who has worked on Systemic Lupus Erythematosus (SLE) for many years and who came up with the chameleon concept. The manuscript captures some recent work on the formation of Z-DNA in bacterial biofilms and their role in inducing anti-Z-DNA antibodies and inflammatory disease. https://lnkd.in/eCquziCu

3

I've decided it's time to start writing again, and this time I'm organizing it via a new Substack publication (https://lnkd.in/gyiitPCn). I plan to share some thoughts every few weeks on the challenges and exciting opportunities I see in building solutions in the tech-meets-bio world. If you're interested in listening to the ramblings of a semi-mad man, feel free to subscribe 🙂 This week's post (https://lnkd.in/gNFdyAT3) centers on what I call a "Meta-Experiment", and why I think this framing is helpful in operating any business, but especially a DeepTech one like platform-based biotech companies. It's also a bit of a prerequisite read for some thoughts I'm working on now around the Recursion-Exscientia tie-up announcement from a couple weeks ago.

15

3 Comments